NO20004795D0 - Peptidbaserte forbindelser - Google Patents

Peptidbaserte forbindelser

Info

Publication number
NO20004795D0
NO20004795D0 NO20004795A NO20004795A NO20004795D0 NO 20004795 D0 NO20004795 D0 NO 20004795D0 NO 20004795 A NO20004795 A NO 20004795A NO 20004795 A NO20004795 A NO 20004795A NO 20004795 D0 NO20004795 D0 NO 20004795D0
Authority
NO
Norway
Prior art keywords
diseases
peptide
based compounds
relates
compounds
Prior art date
Application number
NO20004795A
Other languages
English (en)
Norwegian (no)
Inventor
Alan Cuthbertson
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Priority to NO20004795A priority Critical patent/NO20004795D0/no
Publication of NO20004795D0 publication Critical patent/NO20004795D0/no
Priority to EP01972816A priority patent/EP1358206B1/de
Priority to KR1020037004291A priority patent/KR100896983B1/ko
Priority to JP2002531159A priority patent/JP4948742B2/ja
Priority to CN01816130A priority patent/CN1462276A/zh
Priority to AU2001292456A priority patent/AU2001292456B2/en
Priority to PCT/NO2001/000390 priority patent/WO2002026776A2/en
Priority to CA002420577A priority patent/CA2420577A1/en
Priority to AT01972816T priority patent/ATE519776T1/de
Priority to AU9245601A priority patent/AU9245601A/xx
Priority to CNA2008101907788A priority patent/CN101531704A/zh
Priority to NO20031323A priority patent/NO331535B1/no
Priority to US10/395,500 priority patent/US7737252B2/en
Priority to US12/814,621 priority patent/US8258101B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
NO20004795A 2000-09-26 2000-09-26 Peptidbaserte forbindelser NO20004795D0 (no)

Priority Applications (14)

Application Number Priority Date Filing Date Title
NO20004795A NO20004795D0 (no) 2000-09-26 2000-09-26 Peptidbaserte forbindelser
CNA2008101907788A CN101531704A (zh) 2000-09-26 2001-09-25 肽基化合物
PCT/NO2001/000390 WO2002026776A2 (en) 2000-09-26 2001-09-25 Peptide-based compounds
KR1020037004291A KR100896983B1 (ko) 2000-09-26 2001-09-25 펩티드-기재 화합물
JP2002531159A JP4948742B2 (ja) 2000-09-26 2001-09-25 ペプチド系化合物
CN01816130A CN1462276A (zh) 2000-09-26 2001-09-25 肽基化合物
AU2001292456A AU2001292456B2 (en) 2000-09-26 2001-09-25 Peptide-based compounds
EP01972816A EP1358206B1 (de) 2000-09-26 2001-09-25 Peptidische verbindungen
CA002420577A CA2420577A1 (en) 2000-09-26 2001-09-25 Peptide-based compounds
AT01972816T ATE519776T1 (de) 2000-09-26 2001-09-25 Peptidische verbindungen
AU9245601A AU9245601A (en) 2000-09-26 2001-09-25 Peptide-based compounds
NO20031323A NO331535B1 (no) 2000-09-26 2003-03-24 Peptidbaserte forbindelser, fremgangsmate for fremstilling og farmasoytiske sammensetninger omfattende slike, samt anvendelse.
US10/395,500 US7737252B2 (en) 2000-09-26 2003-03-24 Peptide-based compounds
US12/814,621 US8258101B2 (en) 2000-09-26 2010-06-14 Peptide-based compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20004795A NO20004795D0 (no) 2000-09-26 2000-09-26 Peptidbaserte forbindelser

Publications (1)

Publication Number Publication Date
NO20004795D0 true NO20004795D0 (no) 2000-09-26

Family

ID=19911612

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20004795A NO20004795D0 (no) 2000-09-26 2000-09-26 Peptidbaserte forbindelser
NO20031323A NO331535B1 (no) 2000-09-26 2003-03-24 Peptidbaserte forbindelser, fremgangsmate for fremstilling og farmasoytiske sammensetninger omfattende slike, samt anvendelse.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20031323A NO331535B1 (no) 2000-09-26 2003-03-24 Peptidbaserte forbindelser, fremgangsmate for fremstilling og farmasoytiske sammensetninger omfattende slike, samt anvendelse.

Country Status (10)

Country Link
US (2) US7737252B2 (de)
EP (1) EP1358206B1 (de)
JP (1) JP4948742B2 (de)
KR (1) KR100896983B1 (de)
CN (2) CN1462276A (de)
AT (1) ATE519776T1 (de)
AU (2) AU2001292456B2 (de)
CA (1) CA2420577A1 (de)
NO (2) NO20004795D0 (de)
WO (1) WO2002026776A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
WO2002053703A2 (en) * 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
EP1481683A1 (de) 2003-05-30 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. P-Selectin Zeilgerichtetenligand und dessen Zusammenstezung
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
NO20035748D0 (no) * 2003-12-19 2003-12-19 Amersham Health As Optisk avbildning av sårbar arteriosklerose
DE602005025911D1 (de) * 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
EP1833512A1 (de) 2005-01-06 2007-09-19 GE Healthcare AS Optische bilddarstellung
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
EP2056886A2 (de) * 2006-08-28 2009-05-13 GE Healthcare Limited 68ga-markierte radiopharmazeutika auf peptidbasis
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
KR101016214B1 (ko) * 2007-04-23 2011-02-25 한국과학기술연구원 근적외선 형광체가 결합된 담즙산-글라이콜키토산 복합체나노입자를 포함하는 류마티스 관절염 진단용 조영제
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
PL3152226T3 (pl) * 2014-06-06 2019-10-31 Univ Muenchen Tech Modyfikowane cyklopentapeptydy i ich zastosowania
EP3037820A1 (de) * 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Zellerkennungsverfahren und Reagenzien mit lösbarem Etikettierungsteil
KR20180100302A (ko) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
SE463651B (sv) 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
JP2833766B2 (ja) 1987-07-16 1998-12-09 ニユコメド・アクシエセルカペト アミノポリカルボン酸およびその誘導体
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
IE901736L (en) 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
GB8914020D0 (en) * 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
US5078985A (en) * 1989-08-09 1992-01-07 Rhomed, Incorporated Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
GB9007408D0 (en) 1990-04-02 1990-05-30 Nycomed As Compositions
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9120508D0 (en) 1991-09-26 1991-11-06 Nycomed As Diagnostic agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
FR2699595B1 (fr) * 1992-12-23 1995-01-20 Snecma Dispositif de guidage en rotation d'un anneau de commande d'aubes pivotantes.
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DE69527194T2 (de) 1994-03-28 2003-02-06 Daiichi Pharmaceutical Co., Ltd. Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
RU2147243C1 (ru) 1994-09-27 2000-04-10 Нюкомед Имагинг А/С Контрастное средство
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
ATE308981T1 (de) 1995-08-14 2005-11-15 Scripps Research Inst Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese
JP3900305B2 (ja) 1995-09-11 2007-04-04 ザ バーナム インスティテュート インビボにおいて選択された器官または組織に帰巣する分子および同分子を同定する方法
CA2242647A1 (en) 1996-01-10 1997-07-17 Amersham Health As Contrast media
AU709778B2 (en) 1996-02-09 1999-09-09 Steinel Gmbh & Co. Kg Device for evaporating a liquid active substance
ES2197986T3 (es) 1996-02-19 2004-01-16 Amersham Health As Mejoras introducidas en o relacionadas con agentes de contraste.
CA2265484C (en) 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
GB9624918D0 (en) 1996-11-29 1997-01-15 Nycomed Imaging As Particulate components
CA2291323A1 (en) 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
IL137681A0 (en) 1998-02-06 2001-10-31 Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
AU2662999A (en) 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
CA2405469C (en) * 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
US6559279B1 (en) * 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser

Also Published As

Publication number Publication date
US8258101B2 (en) 2012-09-04
JP2004509975A (ja) 2004-04-02
US20100256330A1 (en) 2010-10-07
EP1358206B1 (de) 2011-08-10
US20030176639A1 (en) 2003-09-18
US7737252B2 (en) 2010-06-15
CN101531704A (zh) 2009-09-16
WO2002026776A2 (en) 2002-04-04
ATE519776T1 (de) 2011-08-15
AU9245601A (en) 2002-04-08
NO20031323L (no) 2003-03-24
WO2002026776A3 (en) 2003-08-28
EP1358206A2 (de) 2003-11-05
NO20031323D0 (no) 2003-03-24
KR100896983B1 (ko) 2009-05-14
AU2001292456B2 (en) 2008-02-28
NO331535B1 (no) 2012-01-23
CA2420577A1 (en) 2002-04-04
KR20030061811A (ko) 2003-07-22
JP4948742B2 (ja) 2012-06-06
CN1462276A (zh) 2003-12-17

Similar Documents

Publication Publication Date Title
NO20004795D0 (no) Peptidbaserte forbindelser
PL1648925T3 (pl) Środki obrazujące na bazie bicyklicznych peptydów
ATE364618T1 (de) Antikörper gegen das muc18-antigen
TR200000913T2 (tr) Tıbbi maddeler
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
EP1467757A4 (de) Verwendung von antikörpern gegen das muc18-antigen
MXPA04000173A (es) Compuestos basados en peptidos.
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
ATE240395T1 (de) Antikörper gegen e-selektin
DE60038252D1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer&#39;s disease
ATE355288T1 (de) Verbindungen und therapeutische methoden
EP1706145A4 (de) Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper
EP1532162A4 (de) Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
PL2101826T3 (pl) Znakowane izotopowo związki na bazie peptydów i ich zastosowania